Your browser is no longer supported. Please, upgrade your browser.
INNT Innovate Biopharmaceuticals, Inc. daily Stock Chart
Innovate Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-7.26 Insider Own3.90% Shs Outstand26.98M Perf Week29.83%
Market Cap362.88M Forward P/E- EPS next Y- Insider Trans- Shs Float24.81M Perf Month0.15%
Income-22.70M PEG- EPS next Q- Inst Own5.50% Short Float2.90% Perf Quarter-47.56%
Sales0.90M P/S403.20 EPS this Y16.70% Inst Trans- Short Ratio3.05 Perf Half Y121.69%
Book/sh0.37 P/B36.35 EPS next Y- ROA-435.10% Target Price- Perf Year149.07%
Cash/sh0.48 P/C27.91 EPS next 5Y- ROE- 52W Range3.43 - 50.50 Perf YTD120.49%
Dividend- P/FCF- EPS past 5Y- ROI1305.30% 52W High-73.37% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin-1.90% 52W Low292.13% ATR1.24
Employees24 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)54.07 Volatility12.00% 10.44%
OptionableYes Debt/Eq0.44 EPS Q/Q72.90% Profit Margin- Rel Volume1.77 Prev Close11.06
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume235.59K Price13.45
Recom- SMA2014.84% SMA50-16.16% SMA20022.54% Volume417,905 Change21.61%
Jun-13-18 07:10PM  Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D. GlobeNewswire
Jun-04-18 05:54PM  Is Innovate Biopharmaceuticals Incs (NASDAQ:INNT) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-31-18 07:02AM  Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on Friday, June 8, 2018, at 11:30AM GlobeNewswire
May-22-18 08:01AM  Innovate Biopharmaceuticals Scheduled to Present at BIO 2018 Convention in Boston on Tuesday, June 5, 2018, at 4:45PM GlobeNewswire
May-17-18 03:06PM  Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C. GlobeNewswire
May-16-18 09:10AM  Innovate Biopharmaceuticals Reports First Quarter 2018 Key Financial and Corporate Highlights GlobeNewswire +6.90%
May-09-18 02:07PM  Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference GlobeNewswire -7.76%
Apr-10-18 06:31PM  Who Owns Innovate Biopharmaceuticals Inc (NASDAQ:INNT)? Simply Wall St.
Apr-05-18 06:03AM  Innovate Biopharmaceuticals, Inc. to Present at the H.C. Wainwright Annual Global Life Sciences Conference on April 9, 2018 GlobeNewswire
Mar-24-18 12:01AM  [$$] Charting the Market
Mar-13-18 07:32AM  Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer GlobeNewswire -9.69%
Mar-07-18 07:32AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, 2018, Tuesday at 8:40 AM ET GlobeNewswire -10.34%
Mar-06-18 08:20AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical ACCESSWIRE -16.18%
Feb-13-18 11:19AM  How Does Innovate Biopharmaceuticals Inc (NASDAQ:INNT)s Prospect Stack Up Next To Its Healthcare Peers? Simply Wall St.
Feb-07-18 10:30AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:30PM ET GlobeNewswire -11.04%
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the company holds global rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase 3 clinical trial. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.